Actinium-225 supply cannot keep pace with growing demand. We are solving this at scale. Transmutex is developing HI-BEAM to produce actinium-225, a radioactive isotope used in targeted cancer treatments, at industrial scale. Our technology combines a high-energy cyclotron, thorium targets and proprietary extraction technology. It uses abundant thorium-232, without relying on highly radioactive material or legacy nuclear waste inventories. For isotope supply, partnerships or investment, contact info@transmutex.com.
| Website | http://www.transmutex.com |
| Employees | 51 (47 on RocketReach) |
| Founded | 2019 |
| Address | Chemin de Blandonnet 8, Vernier, Geneva 1214, CH |
| Technologies |
JavaScript
,
HTML
,
Twitter
+13 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing |
| Keywords | Nuclear Energy, Advanced Nuclear, Nuclear Technology, Nuclear Innovation, Reactor Technology, Nuclear Safety, Nuclear Fuel, Nuclear Power, Nuclear Proliferation, Nuclear Waste, Clean Energy, Nuclear Reactors, Nuclear Fusion, Alternative Energy, Energy Innovation, Nuclear Fission, Sustainable Energy, Radioactive Waste, Renewable Energy, Energy Technology |
| Competitors | Thermo Fisher Scientific, Brookhaven National Laboratory, naa.com, Interact Analysis, Canberra Industries, Sandia National Laboratories, Oak Ridge National Laboratory, Los Alamos National Laboratory, Cameco Corporation +34 more (view full list) |
Looking for a particular TRANSMUTEX employee's phone or email?
Franklin Servan-Schreiber is the Co-Founder, Chairman and CEO of TRANSMUTEX.
47 people are employed at TRANSMUTEX.
TRANSMUTEX is based in Vernier, Geneva.